Empagliflozin is used in the treatment of 2 diabetic adults with diet combined with exercise who fail to achieve adequate glycemic control to improve glycemic control.
Empagliflozin mainly reduces plasma glucose levels by inhibiting the expression of SGLT-2, reducing renal glucose reabsorption and increasing the excretion of glucose in urine, and its hypoglycemic effect does not depend on β cell function and insulin resistance.
|Appearance||White to off-white powder||Confirmed|
|Loss on drying||≤0.5%||0.2%|
|Residue on ignition||≤0.5%||0.1%|
|Appearance:||White to off-white powder|
|Package details:||100g/bottle; 1kg/bag|
Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!